AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial
09/07/2026 07:10
AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial July 9 (Reuters) - AstraZeneca AZN.L said on Thursday that its drug Wainua, made in partnership with Ionis IONS.O, failed to meet the main goal of reducing cardiovascular deaths and recurring heart problems in a late-stage trial.
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Janane Venkatraman)
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study